Compare AU
Compare DRUG vs. BBUS
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the BetaShares Us Eqy Strong Bear - Ch (Hedge Fund) (BBUS). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | BBUS | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 64 | 11 |
Median incremental investment | $943.50 | $4,993.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,978.96 | $2,069.44 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | BBUS | |
---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | BBUS.AX was created on 2015-08-24 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to help investors profit from, or protect against, a declining U.S. share market. It seeks to generate magnified returns that are negatively correlated to the returns of the U.S. share market (as measured by the S&P 500 index), hedged to Australian dollars. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | S&P500 EMINI FUT SEP24 (0 %) AUD - AUSTRALIA DOLLAR (98.14 %) USD - UNITED STATES DOLLAR (1.86 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Other (73.66 %) Communication Services (26.34 %) |
Top 3 countries | United States (23.96 %) Ireland (0.52 %) France (0.00 %) | |
Management fee | 0.57 % | 1.38 % |
Key Summary
DRUG | BBUS | |
---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.57 % | 1.38 % |
Price | $8.53 | $4.64 |
Size | $197.947 million | $155.723 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 1.89 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 26/08/2015 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | BBUS | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 64 | 11 |
Median incremental investment | $943.50 | $4,993.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,978.96 | $2,069.44 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | BBUS | |
---|---|---|
Pros |
| |
Cons |
|
DRUG | BBUS |
---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |